The company has caught up with Syndax and overtaken Kura in the first-line menin inhibitor race.

The company heralds a pivotal win with its menin inhibitor, but investors want to see data.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

Autolous, Syndax, Jazz and Shorla get US approvals in a quiet month.

Party season approaches; but first, conferences.

Syndax scored the first menin approval, but Kura is first with a licensing deal.

Response rates in relapsed NPM1-mutant AML look slightly worse than before, but QTc prolongation could be the real worry.

Kura will see more combo data, while a new contender from Sumitomo emerges.